Pharmaceuticals company Alivus Life Sciences announced 9MFY25 & Q3FY25 results Revenue from operations for Q3FY25 reached Rs 6,418 million, a growth of 12.0% YoY and 26.6% QoQ. For 9MFY25, revenue from operations was Rs 17,373 million. For Q3FY25, EBITDA was at Rs 2,008 million, a growth of 15.2% YoY and 40.5% QoQ. EBITDA margins were at 31.3%, up 90 bps YoY and 310 bps QoQ. EBITDA for 9MFY25 was at Rs 5,086 million while EBITDA margins stood at 29.3%. PAT for the quarter stood at Rs 1,370 million and PAT margins were at 21.3%. For 9MFY25, the company recorded PAT of Rs 3,438 million with PAT margins of 19.8%. During 9MFY25, the company generated a strong free cash flow of Rs 1,838 million leading to Cash and Cash Equivalents (including short term investments) of Rs 4,993 million as of 31 December 2024. Yasir Rawjee, MD & CEO, Alivus Life Sciences, said: “The start of the new year marks a notable shift for us as we transition to Alivus Life Sciences. I am pleased to report that our Q3 performance reflects this renewed energy, with growth across both GPL and Non-GPL segments. Geographically, regions like India, Europe, ROW and Japan contributed to the growth. Our quest for high-quality, innovative solutions and scalability continues, in order to build a sustainable business over the long term.” Tushar Mistry, CFO, Alivus Life Sciences, said: “Our emphasis on achieving quality growth has delivered encouraging outcomes with highest ever quarterly revenue at Rs 6,418 million. This translated to steady gross margins at ~56%, while our EBITDA grew by 15.2% YoY, underscoring our ability to cater a diversified product range while maintaining stringent cost efficiency." Result PDF